Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSNOR Phenotyping and GSNO Challenge in Severe Asthma
NCT03926741Phase 1Completed
- Start
- Apr 2019
- Primary completion
- Feb 2024
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of S-nitrosoglutathione in asthma (2 arms). Primary endpoints: Fractional Exhaled Nitric Oxide and Change in Forced Expiratory Volume in 1 Second. Started Apr 2019; status: completed.
02
Drugs
S-nitrosoglutathione
03
Conditions
asthma
Beyond the preview
Go deeper on NCT03926741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03926741.